Datamonitor's Global Pharmaceuticals, Biotechnology & Life Sciences industry profile is an essential resource for top-level data and analysis covering the global pharmaceuticals, biotechnology & life ...
This Database Table is a one-page table of hard-to-find numerical information. The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif ...
Koncept Analytics | 25 pages | Juin 2008 | Anglais
This industry profile helps to gain an insight into the evolution of the industry and competitive dynamics prevalent in the market. It discusses the significant developments in the industry and ana ...
High clinical development costs coupled with declining drug discovery success rates have meant that pharmaceutical companies must re-evaluate their drug development process in order to reduce attritio ...
Datamonitor's Protherics PLC SWOT company profile is the essential source for top-level company data and information. The report examines the companys key business structure and operations, histor ...
BioInformatics | 152 pages | Octobre 2003 | Anglais
This report is designed to help life science product managers understand customers in the DNA purification market and the factors that drive their purchasing behavior ...
This Database Table is a one-page table of hard-to-find numerical information. The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif ...
Global Industry Analyst | 410 pages | Janvier 2006 | Anglais
This report analyzes the worldwide markets for Agricultural Biotechnology in Millions of US$. he specific product segments analyzed are Transgenic Seeds/Crops, and Biopesticides. The sub product ...
This report is an incisive study of all the aspects of an industry along with an outlook for potential developments. The report aims to provide the reader with appropriate information for sharper ...
The blockbuster model now delivers just 5% return on investment and only one in six new drug prospects will deliver returns above their cost of capital, as a result competitive pressures and falling R ...